Astellas Pharma Inc. has presented several data on its drug XOSPATA, which shows promising results for AML disease. The company also announced top management personnel changes recently. They entered into an exclusive license agreement with Evopoint Bioscience for a novel clinical-stage ADC. They also have a partnership with Pfizer where they announced survival results from the EMBARK study. Astellas' Q1 2026 results showed a positive trend with the company moving towards renewable energy by closing 6 datacenters and moving to Azure. However, the company also faced a setback with an expat sentenced to prison. There is ongoing investment in R&D as well, touting a new Cambridge drug research center. The company's latest Q2 results showed an increase in revenue by 10% and a surge in profit by 54%. Additionally, the company has entered into technology agreements with Ajinimoto and has also launched new drugs. Collaborations are also in motion with various institute like Nikon Instruments and MBC BioLabs. However, a key trial for pancreatic cancer did not meet its primary endpoint.
Astellas Pharma Inc. News Analytics from Thu, 19 Dec 2024 08:00:00 GMT to Fri, 05 Dec 2025 14:25:46 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 2
